Mahmoud M Morsy, Ahmed Y Azzam, Osman Elamin, Adam Elswedy, Abdulqadir J Nashwan
INTRODUCTION: Acute myeloid leukemia (AML) is a significant hematological malignancy in the United States, with a high mortality rate and limited treatment options. CAR T-cell therapy, a new and promising treatment, is being investigated for its efficacy and safety in AML. This meta-analysis aims to assess the safety and efficacy of CAR T-cell therapy in AML, considering various subgroups such as study location, study design, prior transplantation status, conditioning regimen, and CAR T-cell source...
April 1, 2024: Leukemia Research
Süreyya Yiğit Kaya, Yaşa Gül Mutlu, Ümit Yavuz Malkan, Özgür Mehtap, Fatma Keklik Karadağ, Gülten Korkmaz, Tuğrul Elverdi, Güray Saydam, Gülsüm Özet, Muhlis Cem Ar, Elif Melek, Senem Maral, Leylagül Kaynar, Ömür Gökmen Sevindik
BACKGROUND: Hairy cell leukemia (HCL) is a rare mature B-cell malignancy that is primarily treated with purine analogues. However, relapse remains a significant challenge, prompting the search for alternative therapies. The BRAF V600E mutation prevalent in HCL patients provides a target for treatment with vemurafenib. PATIENTS AND METHODS: This multicenter retrospective study included nine patients with relapsed/refractory (R/R) HCL from six different centers. Patient data included demographics, prior treatments, clinical outcomes, and adverse events...
March 29, 2024: Leukemia Research
Alberto Risueño, Wendy L See, Iryna Bluemmert, Stéphane de Botton, Courtney D DiNardo, Amir T Fathi, Andre C Schuh, Pau Montesinos, Paresh Vyas, Thomas Prebet, Anita Gandhi, Maroof Hasan
Limited treatment options are available for patients with relapsed/refractory acute myeloid leukemia (R/R AML). We recently reported results from the phase 3 IDHENTIFY trial (NCT02577406) showing improved response rates and event-free survival with enasidenib monotherapy compared with conventional care regimens (CCR) in heavily pretreated, older patients with late-stage R/R AML bearing IDH2 mutations. Here we investigated the prognostic impact of mutational burden and different co-mutation patterns at study entry within the predominant IDH2 variant subclasses, IDH2-R140 and IDH2-R172...
March 27, 2024: Leukemia Research
Chandrasekar Muthiah, Ravi Narra, Ehab Atallah, Wanlin Juan, Aniko Szabo, Guru Subramanian Guru Murthy
In the last decade, novel agents such as BTK and BCL-2 inhibitors have revolutionized treatment of CLL/SLL, with clinical trials showing improved overall survival compared to chemotherapeutic agents. However, studies examining whether they have improved overall survival at the population level are lacking. We evaluated this by conducting a retrospective analysis of CLL/SLL patients registered in the National Cancer Institute's surveillance epidemiology and end results (SEER) database, analyzing overall survival (OS) in periods pre- and post-availability of novel agents, along with demographic information...
March 22, 2024: Leukemia Research
Mia Brunetti, Isabella A Iasenza, Adrianne L Jenner, Noël J-M Raynal, Kolja Eppert, Morgan Craig
Over the years, the overall survival of older patients diagnosed with acute myeloid leukemia (AML) has not significantly increased. Although standard cytotoxic therapies that rapidly eliminate dividing myeloblasts are used to induce remission, relapse can occur due to surviving therapy-resistant leukemic stem cells (LSCs). Hence, anti-LSC strategies have become a key target to cure AML. We have recently shown that previously approved cardiac glycosides and glucocorticoids target LSC-enriched CD34+ cells in the primary human AML 8227 model with more efficacy than normal hematopoietic stem cells (HSCs)...
March 16, 2024: Leukemia Research
Ebru Kilic Gunes, Sureyya Yigit Kaya, Fatih Yaman, Mustafa Kemal Yeniay, Kurtulus Vural, Melda Comert, Omur Gokmen Sevindik, Neslihan Andic, Simten Dagdas, Ilknur Nizam Ozen, Leylagul Kaynar, Filiz Yavasoglu, Gulsum Ozet, Volkan Karakus, Meltem Ayli
INTRODUCTION: Thrombocytopenia is among the most common complications following hematopoietic stem cell transplantation and is associated with increased mortality and morbidity with no standard treatment yet. In this multicenter and retrospective study, we aim to present our multi-center experience of Eltrombopag treatment in patients with isolated thrombocytopenia following HSCT. MATERIAL-METHOD: A total of 73 patients from 5 centers who underwent autologous or allogeneic stem cell transplantation, had no primary disease relapse, all of whom had neutrophil engraftment, complete chimerism, and who were diagnosed with Prolonged Isolated Thrombocytopenia (PIT) or Secondary Failure Of Platelet Recovery (SFPR) were included in the study...
March 15, 2024: Leukemia Research
Maura R V Ikoma-Colturato, Alef Rafael Severino, Juliana Fernanda Dos Santos Tosi, Camila Marques Bertolucci, Yeda Midori Nakamura Cuoco, Ederson Roberto de Mattos, Iago Colturato, Fernanda Barbieri Rodrigues Silva, Mair Pedro de Souza, Anderson João Simione, Vergilio Antonio Rensi Colturato
No abstract text is available yet for this article.
March 13, 2024: Leukemia Research
Guillermo Garcia-Manero, Maciej Kazmierczak, Agnieszka Wierzbowska, Chun Yew Fong, Michael K Keng, Gianluca Ballinari, Francesco Scarci, Lionel Adès
Non-intensive therapies such as the hypomethylating agent (HMA) azacitidine (AZA) have been used in patients with AML ineligible for intensive induction chemotherapy (IC) or stem cell transplant due to advanced age, comorbidities, and/or risk factors. However, response rates and survival remain dismal. Pre-clinical studies indicate the epigenetic combination of HMAs and HDAC inhibitors induce re-expression of silenced genes synergistically. The activity of pracinostat, an oral pan-HDAC inhibitor, has been shown in xenograft tumor models of AML and promising efficacy was seen in a Phase 2 study...
March 12, 2024: Leukemia Research
Xiaoyi Hu, Asiri Ediriwickrema, Atif Saleem, Brent Tan, Naveen Pemmaraju, Gabriel N Mannis
No abstract text is available yet for this article.
March 11, 2024: Leukemia Research
Mara N Zeissig, Duncan R Hewett, Krzysztof M Mrozik, Vasilios Panagopoulos, Craig T Wallington-Gates, Andrew Spencer, Sandra M Dold, Monika Engelhardt, Kate Vandyke, Andrew C W Zannettino
BACKGROUND: The proteasome inhibitor bortezomib is one of the primary therapies used for the haematological malignancy multiple myeloma (MM). However, intrinsic or acquired resistance to bortezomib, via mechanisms that are not fully elucidated, is a barrier to successful treatment in many patients. Our previous studies have shown that elevated expression of the chemokine receptor CCR1 in MM plasma cells in newly diagnosed MM patients is associated with poor prognosis. Here, we hypothesised that the poor prognosis conferred by CCR1 expression is, in part, due to a CCR1-mediated decrease in MM plasma cell sensitivity to bortezomib...
March 7, 2024: Leukemia Research
Pouya Goleij, Pantea Majma Sanaye, Mehregan Babamohamadi, Mohammad Amin Khazeei Tabari, Roshanak Amirian, Aryan Rezaee, Hamed Mirzaei, Alan Prem Kumar, Gautam Sethi, Sarvin Sadreddini, Philippe Jeandet, Haroon Khan
Lymphoma is a cancer affecting the lymphatic system that fights infections and diseases. In addition to surgery, radiotherapy, and chemotherapy, novel approaches have recently been investigated, such as phytostilbenes in treating lymphoma. Phytostilbenes are natural compounds present in various plants and have been shown to have different therapeutic effects, including anticancer properties. Resveratrol is a main phytostilbene with various derivates followed by pterostilbene and piceatannol. Studies have revealed that phytostilbenes can suppress the growth and proliferation of lymphoma cells by inducing apoptosis and inhibiting specific enzyme activity in cancer cell survival...
February 24, 2024: Leukemia Research
Yulia Sidi, Cassie Dong, Yujun Wu, Douglas V Faller
Despite emerging novel therapies, treating acute myeloid leukemia (AML) remains challenging. Complexities persist in designing pivotal clinical trials and establishing acceptable endpoints for AML. Recent FDA guidance for drug and biological products development for AML outlines considerations for trial design. The guidance defines overall survival (OS) and event-free survival (EFS) as endpoints representing clinical benefit for AML therapies without curative intent. We highlight the EFS definition, particularly the assignment of day 1 as the event date for patients with induction treatment failures (ITFs), as recommended in the guidance...
February 23, 2024: Leukemia Research
Afaf E G Osman, Anton Rets, Ami B Patel
No abstract text is available yet for this article.
February 22, 2024: Leukemia Research
Gabriela Sanchez-Petitto, Olga G Goloubeva, Jack Masur, James Childress, Tahreem Iqbal, Max An, Safwan Muhammad, Justin Lawson, Grace Li, Brian Barr, Ashkan Emadi, Jennie Y Law, Seung Tae Lee, Vu H Duong, Maria R Baer, Sandrine Niyongere
Incidence of both acute myeloid leukemia (AML) and cardiovascular disease (CVD) increases with age. We evaluated whether pre-existing CVD impacts clinical outcomes in AML. We retrospectively evaluated 291 consecutive adult AML patients treated at our institution, 2014-2020. Pretreatment comorbidities were identified by chart review. Outcomes included complete remission (CR) and CR with incomplete count recovery (CRi) rates, disease-free survival (DFS), overall survival (OS) and incidence of cardiovascular adverse events...
February 20, 2024: Leukemia Research
Demircan Özbalcı, Mehmet Erdoğan, Emine Güçhan Alanoğlu, Sevim Süreyya Şengül, Kamuran Yüceer, Hande Nur Eroğlu, Samet Yağcı
INTRODUCTION BACKGROUND: This study evaluated the impact of adipose tissue indices on prognosis of HL. METHODS: Fifty-five patients with newly diagnosed Hodgkin Lymphoma were evaluated retrospectively for association with adipose tissue indices (total abdominal tissue volume, radiodensity, subcutaneous and visceral adipose tissue SUVmax value and prognostic factors for Hodgkin Lymphoma such as IPS-3, IPS-7, stage, sedimentation, progression free and overall survival...
February 15, 2024: Leukemia Research
Haruka Sudo, Yasuhiro Tonoyama, Emi Ikebe, Hiroo Hasegawa, Hidekatsu Iha, Yo-Ichi Ishida
Adult T-cell leukemia/lymphoma (ATL), caused by human T-cell leukemia virus type-1 (HTLV-1) infection, is a malignant hematologic cancer that remains difficult to cure. We herein established a biomarker identification strategy based on the total cell proteomics of cultured ATL cells to search for novel ATL biomarkers. Four protocols with a combination of selected conditions based on lysis buffers and addition agents for total cell proteomics were used for a differential analysis between the ATL cell group (consisting of 11 cell lines), HTLV-1-infected cell group (consisting of 6 cell lines), and HTLV-1-negative cell group (consisting of 6 cell lines)...
February 12, 2024: Leukemia Research
Rongjuan Zhang, Xinhong Yang, Xiaomin Shi, Enhong Xing, Lihong Wang, Changlai Hao, Zhihua Zhang
OBJECTIVE: To explore the involvement of TFEB-mediated autophagy-lysosomal mechanisms in multiple myeloma (MM) during bortezomib treatment. METHODS: MM cells were exposed to bortezomib or subjected to TFEB knockdown. CCK assay was used to assess the cell proliferation. Western blotting and fluorescent staining were conducted to examine autophagy and lysosomes. The TFEB expression pattern was analyzed, and whole transcriptome sequencing was carried out. Additionally, TFEB target genes were predicted using the GTRD(https://gtrd...
February 12, 2024: Leukemia Research
Lili Pan, Yining Li, Huiying Gao, Xiaolin Lai, Yuanhua Cai, Zhixiang Chen, Xiaofan Li, Shao-Yuan Wang
Familial acute myeloid leukemia (AML) pedigrees with germline CCAAT/enhancer-binding protein-α (CEBPA) mutation have been rarely reported due to insufficient knowledge of their clinical features. Here, we report two Chinese families with multiple AML cases carrying germline CEBPA mutations, one of which had 11 cases spanning four consecutive generations. Additionally, we collected clinical data of 57 AML patients from 22 families with germline CEBPA mutations, with 58.3% of them harboring double CEBPA mutations...
February 3, 2024: Leukemia Research
Lara Boucher, Laura Rozalska, Nathalie Sorel, Gaëlle Olivier, Maria Pilar Gallego Hernanz, Emilie Cayssials, Anna Raimbault, Jean-Claude Chomel
No abstract text is available yet for this article.
January 23, 2024: Leukemia Research
Sergio Ramos-Cillan, Daniel Láinez-González, Laura Solan, Carlos Blas, Rocío Salgado, Tamara Castaño, Javier Cornago, Pilar Llamas, Juan Manuel Alonso-Dominguez
No abstract text is available yet for this article.
January 17, 2024: Leukemia Research
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.